Kornimate/medical-research-clean huggingface dataset:
18f-av-1451 autopsy study

Conditions: Alzheimer's Disease

Summary: this study is designed to test the relationship between ante-mortem flortaucipir positron emission tomography (pet) imaging and tau neurofibrillary pathology associated with alzheimer's disease (ad), as measured at autopsy.


Eligibility criteria:
inclusion criteria: * have a projected life expectancy of ≤ 6 months * can tolerate a 20 minute pet scan * give informed consent or have a legally authorized representative to consent for study procedures and brain donation consistent with the legal requirements of the state in which they die exclusion criteria: * aggressively being treated with life sustaining measures * known to have a structural brain lesion that would interfere either with pet imaging or pathological assessment * clinically significant infectious disease * currently receiving any investigational medications except with permission from the study sponsor * participated in an experimental study with an amyloid or tau targeting agent * suspected encephalopathy due to alcoholism or end-stage liver disease * females of childbearing potential * history of risk factors for torsades de pointes or are currently taking medication known to cause qt prolongation
development of a multi-attribute health index: to measure the quality of labour analgesia: the qla index

Conditions: Labour Pain

Summary: the findings of this research will be used to develop a scale for measuring the quality of epidural pain relief achieved during labour and vaginal delivery.

the current lack of a tool to measure the overall quality of neuraxial pain relief provided in labour analgesia trials has produced studies unable to provide clear direction to clinical care and research. our previous work explored and described the underlying dimensions and attributes of quality neuraxial analgesia from the perspectives of labouring women as the initial phase of development of an index to measure this as an outcome in research. we now seek to confirm our findings as well as to generate additional items (descriptors) of quality neuraxial analgesia from the perspectives of parturients and experts (obstetrical anesthesiologists and experienced labour nurses). once generated, the full list of items will be used to in a subsequent study involving only parturients (item reduction phase) to develop a scale permitting global measurement of quality neuraxial labour analgesia. the resulting scale, once validated, will provide researchers with a simple global measure for quality in labour analgesia research. this scale will be used later in our program of research to assist with validation studies of the larger multi-attribute health index we are developing.

Eligibility criteria:
inclusion criteria: 1. use of neuraxial labour analgesia during the current pregnancy 2. native english-speakers 3. term pregnancies (\>37-42weeks) 4. the ability to read and write in english 5. provision of written informed consent. exclusion criteria: 1. women who received im or iv narcotics within 4 hours of epidural/ combined spinal epidural (cse) placement 2. women with evidence or history of maternal cognitive impairment 3. women who experienced a neonatal death during the current pregnancy

Keywords: women receiving labour epidural for most recent delivery
differences in the eradication of helicobacter pylori by different therapies

Conditions: Helicobacter Pylori Infection

Summary: to compare the performance of four treatment regimens for radical treatment of helicobacter pylori, evaluating the efficacy, safety, patient compliance, and socioeconomic evaluation of the four regimens. the four treatment regimens included (1) vonoprazan fumarate + amoxicillin + doxycycline, (2) vonoprazan fumarate + furazolidone + doxycycline, (3) esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline, and (4) esomeprazole + colloidal bismuth tartrate + furazolidone + doxycycline.

a single-center, prospective, open-label, parallel control design was conducted to enroll 100 patients with confirmed helicobacter pylori infection. patients were randomly divided into four groups, respectively accept four treatment regimens including (1) vonoprazan fumarate + amoxicillin + doxycycline, (2) vonoprazan fumarate + furazolidone + doxycycline, (3) esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline, and (4) esomeprazole + colloidal bismuth tartrate + furazolidone + doxycycline. the effectiveness, safety and compliance of the four regimens were compared, and the cost-benefit analysis of the different regimens was conducted. the purpose of this study was to explore the most appropriate treatment plan for radical treatment of helicobacter pylori .

Eligibility criteria:
inclusion criteria: 1. age ≥18 years, ≤80 years 2. urea breath test (ubt) was positive for hp infection; 3. without any anti-hp treatment before 4. endoscopy was performed within 1 month 5. understanding the purpose and procedure of the study, voluntarily participating in the study and signing a written informed consent. exclusion criteria: 1. allergic to drugs used in this clinical study; 2. using ppi, histamine h2 receptor antagonist, antibiotics, bismuth, probiotics or drugs with antibacterial effects within 4 weeks before treatment. 3. using adrenal corticosteroids, non-steroidal anti-inflammatory drugs and anticoagulants 4. the disease or clinical condition that may interfere with the treatment evaluation of the study, such as liver disease, cardiovascular disease, lung disease, kidney disease, metabolic disease, psychiatric disease, or malignant tumor 5. pregnant or lactating women 6. participated in other clinical studies within 3 months prior to the registration of this clinical study 7. suspected history of antibiotic abuse 8. patients with craniocerebral injury, mental illness or epilepsy who cannot communicate with others or other diseases that may affect follow-up
grasshopper: a novel clinical dashboard for radiologists

Conditions: Chest Infection; Pulmonary Edema - Acute

Summary: does a radiology clinical dashboard increase radiologist use of specific reporting language for chest x-rays (cxrs) and thereby decrease rates of unnecessary emergency department (ed) prescriptions and follow-up imaging?

chest x-rays (cxr) are the most common radiologic exam, comprising nearly one third of total kpnc imaging volume. despite high cxr utilization, diagnostic yield is frequently low, partly due to the paucity of clinical information provided to radiologists at the time of cxr interpretation, resulting in frequent nonspecific cxr assessments which include terms like "opacities" instead of diagnostic terms such as "pulmonary edema" or "pneumonia". this may contribute to over-treatment and unnecessary follow-up ct imaging. this study proposes the production deployment, active promotion, and evaluation of an innovative clinical dashboard called grasshopper for radiologists to provide pertinent clinical information at the time of cxr interpretation. the dashboard leverages the electronic medical record to programmatically retrieve, and display select clinical notes, patient lab values, and vital signs. the grasshopper study aims to prospectively evaluate the impact of grasshopper on cxr report specificity in ed settings across 15 kpnc service areas, and on downstream care process measures such as prescription and imaging utilization.

Eligibility criteria:
kaiser permanente northern california cxr is ordered during emergency room visit or inpatient hospitalization

Keywords: ai emergency department radiology imaging
study of human bone marrow mesenchymal stem cells in apap

Conditions: Autoimmune Pulmonary Alveolar Proteinosis

Summary: the purpose of this open-label phase iia clinical trial study is to evaluate the safety and preliminary efficacy of hbmmsc intravenous treatment in patients with apap.

autoimmune pulmonary alveolar proteinosis (apap) is a rare lung disease for which there is no specific drug treatment. currently, the standard treatment strategy for pap is whole-lung lavage (wll), which is invasive and has limited therapeutic efficacy. the purpose of this study is to evaluate the safety and preliminary efficacy of hbmmsc intravenous treatment in patients with apap. the clinical trial intends to involve 10 participants. the trial is expected to last approximately 2 years.

Eligibility criteria:
inclusion criteria: * male or female aged 18 years or older * patients diagnosed with apap by both ct and biopsy (tblb, tbcb, or surgical lung biopsy) or bronchoalveolar perfusion (bal) as well as gm-csf autoantibodies in serum positive * no remission was demonstrated by ct, pulmonary function test results,or blood gas analysis at least 2 times (at least 3 months apart) before enrollment * at rest pao2≤70 mmhg * fertile participants must receive effective medical contraception (for both male and female participants, up to one year after the last study dosing) * voluntary signed informed consent exclusion criteria: * diagnosed with hereditary pap, secondary pap, or another type of pap * received whole lung lavage（wll） therapy within 6 months before enrollment * received previous gm-csf therapy within 6 months before enrollment * received other clinical trial treatment within 3 months before enrollment * participated in other stem cell studies within 1 year before enrollment * inflammatory disease or autoimmune disorder requiring treatment associated with significant immunosuppression (e.g. more than 10 mg/day systemic prednisolone) * active infection (viral, bacterial, fungal or mycobacterial), which may affect the assessment of efficacy in the trial * history of malignant tumors * known allergic reactions to any of the ingredients in the study drug * participants who, in the opinion of the investigator, would aggravate any other serious pre-existing medical condition are not suitable for this trial * women who are known to be pregnant, breastfeeding, have a positive pregnancy test (which will be detected during the screening process), or plan to become pregnant during the trial
study to evaluate d-1553 in combination with in10018 in subjects with solid tumors

Conditions: Solid Tumor

Summary: this is a phase 1/2, open label study of d-1553 in combination with in10018 to assess the safety and tolerability, identify the mtd and rp2d, evaluate the pk properties and antitumor activities in subjects with advanced or metastatic solid tumor with krasg12c mutation


Eligibility criteria:
inclusion criteria: * subject with histologically proven, locally advanced, unresectable and/or metastatic solid tumor, for which no standard treatment is available or the subject is refractory to or intolerant of existing standard treatment. * subject has krasg12c mutation in tumor tissue or other biospecimens (only for phase1b) containing cancer cells or dna. historical, local laboratory result (up to 5 years prior to this study) can be used. * subject has tumor type requirement as follows: advanced or metastatic solid tumors including nsclc and crc. * subject has measurable disease according to recist, v1.1 exclusion criteria: subject with unstable or progressive central nervous system (cns) metastases. * subject with acute myocardial infarction, severe/unstable angina; or with cardiac insufficiency of new york heart association functional classification grade 2 or above. * subject has corrected qt interval using fridericia's formula (qtcf) prolongation at rest, where the mean qtc interval is \> 480 msec based on triplicate measurements of electrocardiogram (ecg). * subject with stroke or other severe cerebrovascular diseases within 12 months before enrollment; * subject with interstitial lung disease or acute lung infection not yet recovered including but not limited to severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infection; * subject is pregnant or lactating.
trans-abdominal fetal pulse oximetry; tissue light scattering and signal integrity

Conditions: Fetal Hypoxia

Summary: the overall purpose of this study is to evaluate maternal-fetal tissue light scattering properties. the objectives of the study are: (i) integrate established mathematical principles of oxygen saturation to model with increasing accuracy the "body in a body" problem of fetus in mother; similar to existing pulse oximeters, the calculations will be integrated into software in the final commercial product; (ii) obtain human measurements against which both computational models and animal data can be compared.

this is a prospective, observational, non-significant risk study. the study involves using non-invasive devices that measure fetal depth and tissue light scattering on the maternal abdomen. ultrasound assessment will be performed, and five images taken at the locations indicated on figure 1. depth to fetus will be recorded along with measurement of all distinctive layers. all images will be captured with minimal probe pressure applied to allow accurate ascertainment of depth. images will be anonymized, and all study data will be coded with a unique identifier. key maternal descriptive statistics will be recorded from the medical record including bmi, height, weight (kg), parity, age and gestational age. the iss device is a customized commercial frequency domain oximeter (imagent, iss inc.; http://www.iss.com/biomedical/instruments/imagent.html) with multiple laser sources and multiple detectors. this instrument is safe, uses non-ionizing radiation. the raydiant oximetry sensing system (ross) device is a non-invasive fetal pulse oximeter that measures fetal arterial oxygen saturation using safe, non-invasive, transabdominal near-infrared spectroscopy. the combination of these two devices makes up the raydiant oximetry gen 3 device. this gen 3 device will be positioned on the maternal abdomen of women volunteers in the late 3rd trimester. this sensor will measure light scattering and absorption for a period of about 10-20 minutes. a second measurement may be obtained for an additional site on the maternal abdomen. the sponsor anticipates this study will require about 6-12 months to enroll all study subjects at all study sites, and another month to complete primary analyses.

Eligibility criteria:
inclusion criteria: 1. women with singleton, healthy pregnancy at gestational age ≥ 36 weeks 2. age \> 18 years 3. willing to come in for testing outside of routine business hours (including saturdays) exclusion criteria: 1. age \<18 2. multiple gestation (twins, triplets) 3. presentation other than vertex or breech 4. \< 36 weeks of gestation
alterations of immunologic mediators during severe sepsis

Conditions: Severe Sepsis

Summary: severe sepsis induces significant changes in expression of insulin- and toll-like receptors, cytokines, markers of apoptosis, and activation of t- and b-lymphocytes.

in patients at early stage of severe sepsis, we investigate the expression of pro- and anti-inflammatory cytokines, chemokines, adhesion-molecules, toll-like receptors, insulin-receptors, markers of apoptosis und of t- and b-cell-activation on a mrna level.

Eligibility criteria:
inclusion criteria: * age \>= 18 y * agreement with study procedures * 3 of 4 sirs-criteria * proven or highly suspected infection * 2 or more sepsis-induced organ failures * start of first sepsis-induced organ failure within the last 36 hours exclusion criteria: * non-agreement with study procedures * signs of severe sepsis with organ failure \> 36 hours * chronic immuno-compromising diseases * chronic therapy with anti-inflammatory drugs * non-curable cancer * chronic renal failure with hemodialysis * pregnancy or breast-feeding

Keywords: sepsis early stage immune system receptors cytokines
association of the neutrophil/lymphocyte ratio with pulmonary complications and mortality in covid-19 patients

Conditions: Covid19; Pulmonary Complication

Summary: the coronavirus disease-19 (covid-19) pandemic is currently a priority for health services worldwide. unlike the severe acute respiratory syndrome-coronavirus (sars-cov) epidemic in 2012, the covid-19 shows specific alterations in the white blood cell count, accentuated in severe cases, and with respiratory failure. among the most relevant data are both lymphopenia, thrombocytopenia, and eosinopenia. the neutrophil lymphocyte index has been beneficial in the evaluation of infectious respiratory processes, showing a sensitivity similar to scales such as curb65 (confusion, uremia, respiratory rate, bp, age ≥ 65 years). because covid-19 infection shows alterations in the blood cell ratio, these indices may be useful in evaluating patients with covid-19 infection.

the hematological alterations in patients with covid-19 divided into two aspects: the main ones, the global leukocyte count, and the individual counts. most of the information about the behavior of blood counts come from cases attended in wuhan, china. at the zhongnan hospital in hubei province, identified that the lymphocyte count was lower in critically ill patients. at the same time, the leukocyte counts were higher in deaths associated with covid-19, this elevation being mainly of neutrophils. the lymphopenia is also a constant data in covid-19 (47.4%), especially in cases that entered the intensive care unit. as in community pneumonia, severe lymphopenia has associated with a high risk of death. a relationship between neutrophils and lymphocytes is called the neutrophil-lymphocyte index. this index is especially useful for predicting respiratory complications, such as for covid-19, where mortality ranges from 2-9% compared to the 2012 epidemic (10%) or middle east respiratory syndrome (37%). in mexico, there is a high prevalence of chronic diseases that increase the risk of covid-19 infection. this study's main objective is to identify the association of blood abnormalities on respiratory complications associated with covid-19 infection. all data were obtained from the clinical records of patients treated by covid-19.

Eligibility criteria:
inclusion criteria: * patients with active covid-19 infection exclusion criteria: * liver failure * active cancer * chronic renal failure * aids * pregnancy

Keywords: pulmonary complications mortality covid-19 neutrophil/lymphocyte ratio
stereotactic mri-guided adaptive radiation therapy (smart) in one fraction

Conditions: Metastatic Carcinoma

Summary: this is a multi-site single arm feasibility study of single-fraction stereotactic mri-guided adaptive radiation therapy (smart) for primary or metastatic carcinoma involving the lung, liver, adrenal gland, abdominal/pelvic lymph node, pancreas, and/or kidney. stereotactic ablative body radiation therapy (sabr) is a highly-focused radiation treatment that gives an intense dose of radiation concentrated on a tumor, while limiting the dose to the surrounding organs.


Eligibility criteria:
inclusion criteria 1. subject must be ≥18 years of age at the time of study enrollment 2. subject must have biopsy-confirmed primary or metastatic carcinoma with involvement of the lung, liver, adrenal gland, pancreas, kidney, and/or abdominal/pelvic lymph node that would receive sabr 3. any lesion that would receive sabr under this study protocol is no larger than 5 cm in greatest dimension 4. 1-10 total lesions that would receive sabr 5. if multiple lesions are treated, they must be at least 3 cm apart 6. eastern cooperative oncology group (ecog) performance status of 0-2 7. life expectancy at least 6 months 8. women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation. abstinence is acceptable if it's the patient preferred method. should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately. 9. patients receiving hormonal therapy or immunotherapy such as immune checkpoint inhibitor that had begun at least 4 weeks prior to sabr will be allowed. exclusion criteria 1. subject has contraindication to having an mri scan 2. subject has central or ultra-central lung tumor that would receive sabr on this study, defined as a lesion located within 2 cm of the trachea and proximal bronchial tree 3. subject has received cytotoxic chemotherapy or investigational agent within 2 weeks of sbrt 4. subject has uncontrolled brain metastases, spinal cord compression, or leptomeningeal carcinomatosis 5. subject has any unresolved toxicity (common terminology criteria for adverse events version 5.0 \> grade 2) from previous anti-cancer therapy 6. subject has any condition in the opinion of the investigator that would interfere with evaluation of study treatment or interpretation of patient safety or study results 7. subject has received prior radiation therapy that directly overlaps any radiation therapy given in this study 8. subject has received radiation therapy that could lead to an unacceptably high risk of clinically significant normal tissue injury due to high cumulative normal tissue dose as determined by the investigator 9. female subject who are pregnant or breastfeeding 10. subject who has received vascular endothelial growth factor (vegf) inhibitor such as bevacizumab within 4 weeks prior to study therapy or planned to receive it within 4 weeks after study therapy.
monitoring patients with severe obesity treated with wegovy® using connected device: real-world data

Conditions: Obesity

Summary: this study involves collecting real-world data on body weight, body composition, cardiovascular parameters, and neurovegetative parameters using a connected scale in patients with severe obesity treated with wegovy®.

obesity is a chronic disease associated with numerous co-morbidities. new treatments for obesity, notably glp-1 (glucagon-like peptide 1) analogs, have led to promising advances. semaglutide 2.4 mg weekly subcutaneous injection, marketed under the brand name wegovy®, was recently approved in france for weight loss in patients with severe obesity and at least one comorbidity. several real-world studies have confirmed the effectiveness of semaglutide in reducing body weight and hba1c. however, few studies have evaluated the kinetics and interindividual variability of changes in body weight and composition as well as cardiovascular health. there appears to be a need for a comprehensive real-world assessment of patients living with severe obesity receiving wegovy®. the tele-sema project involves collecting real-world data on body weight, body composition, cardiovascular and neurovegetative parameters via connected scales in patients with severe obesity treated with wegovy®. the main objectives will be to assess inter-individual weight variability and explore the determinants that may influence weight loss, body composition and possible eating disorders.

Eligibility criteria:
inclusion criteria: * man or woman aged over 18 years * patients who have reached the maximum dose of their treatment with wegovy® * written consent exclusion criteria: * patient on ame (state medical aid) * pregnant or breastfeeding woman * patient who does not speak french * adults under legal protection

Keywords: obesity wegovy semaglutide 2.4 mg/week